Employment Verification for Audentes Therapeutics.

About Audentes Therapeutics

Audentes Therapeutics is a biotechnology company that specializes in developing gene therapy treatments for rare neuromuscular diseases. The company was founded in 2012 and is headquartered in San Francisco, California. Audentes Therapeutics’ gene therapy treatments focus on correcting the underlying genetic mutations that cause neuromuscular diseases, rather than just treating their symptoms. The company’s lead product, AT132, is an investigational gene therapy for X-linked myotubular myopathy (XLMTM), a rare and life-threatening neuromuscular disease that affects infants and young children. AT132 is currently in Phase 1/2 clinical trials, and early results have been promising. In addition to AT132, Audentes Therapeutics has several other gene therapy programs in development for rare neuromuscular diseases, including Pompe disease and Duchenne muscular dystrophy (DMD). The company uses its proprietary adeno-associated virus technology platform to develop these gene therapies. In late 2019, Audentes Therapeutics was acquired by Astellas Pharma, a Japanese pharmaceutical company, for approximately $3 billion. The acquisition is expected to help accelerate the development and commercialization of Audentes’ gene therapies for rare neuromuscular diseases.

The information on this page is not an endorsement of Truv’s services by Audentes Therapeutics and is meant to be purely informational.

Verify Audentes Therapeutics Employees

Truv provides quick, secure and cost-effective employment and income verifications for thousands of verifiers. The process is simple and automated and most employees are verified in under 24 hours. You only pay for successful verification and can save on average 50% compared to competitors. Thousands of verifiers love Truv because it’s been never been easier and more streamlined to verify an employee, learn more.